NTRA Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of 7.1% compared to Natera, Inc.'s net margin of -9.15%. Natera, Inc.'s return on equity of -15.66% beat Delcath Systems, Inc.'s return on equity of 2.81%.

Natera, Inc. has a consensus price target of $259.11, signalling upside risk potential of 24.58%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $21.33 which suggests that it could grow by 121.53%. Given that Delcath Systems, Inc. has higher upside potential than Natera, Inc., analysts believe Delcath Systems, Inc. is more attractive than Natera, Inc..

Natera, Inc. has a beta of 1.683, which suggesting that the stock is 68.297% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.439, suggesting its less volatile than the S&P 500 by 56.086%.

Natera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

Natera, Inc. quarterly revenues are $665.5M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.7M. Natera, Inc.'s net income of $47.3M is higher than Delcath Systems, Inc.'s net income of -$1.9M. Notably, Natera, Inc.'s price-to-earnings ratio is -- while Delcath Systems, Inc.'s PE ratio is 154.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera, Inc. is 12.66x versus 4.45x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health, Inc. has a net margin of 7.1% compared to Natera, Inc.'s net margin of -45.68%. Natera, Inc.'s return on equity of -15.66% beat Guardant Health, Inc.'s return on equity of -8518.58%.

Natera, Inc. has a consensus price target of $259.11, signalling upside risk potential of 24.58%. On the other hand Guardant Health, Inc. has an analysts' consensus of $130.64 which suggests that it could grow by 39.23%. Given that Guardant Health, Inc. has higher upside potential than Natera, Inc., analysts believe Guardant Health, Inc. is more attractive than Natera, Inc..

Natera, Inc. has a beta of 1.683, which suggesting that the stock is 68.297% more volatile than S&P 500. In comparison Guardant Health, Inc. has a beta of 1.644, suggesting its more volatile than the S&P 500 by 64.445%.

Natera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera, Inc. pays -- of its earnings as a dividend. Guardant Health, Inc. pays out -- of its earnings as a dividend.

Natera, Inc. quarterly revenues are $665.5M, which are larger than Guardant Health, Inc. quarterly revenues of $281.3M. Natera, Inc.'s net income of $47.3M is higher than Guardant Health, Inc.'s net income of -$128.5M. Notably, Natera, Inc.'s price-to-earnings ratio is -- while Guardant Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera, Inc. is 12.66x versus 12.33x for Guardant Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of 7.1% compared to Natera, Inc.'s net margin of 28.79%. Natera, Inc.'s return on equity of -15.66% beat Illumina, Inc.'s return on equity of 35.12%.

Natera, Inc. has a consensus price target of $259.11, signalling upside risk potential of 24.58%. On the other hand Illumina, Inc. has an analysts' consensus of $136.11 which suggests that it could grow by 6.85%. Given that Natera, Inc. has higher upside potential than Illumina, Inc., analysts believe Natera, Inc. is more attractive than Illumina, Inc..

Natera, Inc. has a beta of 1.683, which suggesting that the stock is 68.297% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.490, suggesting its more volatile than the S&P 500 by 49.007%.

Natera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera, Inc. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

Natera, Inc. quarterly revenues are $665.5M, which are smaller than Illumina, Inc. quarterly revenues of $1.2B. Natera, Inc.'s net income of $47.3M is lower than Illumina, Inc.'s net income of $334M. Notably, Natera, Inc.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 23.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera, Inc. is 12.66x versus 4.58x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GeneDx Holdings Corp. has a net margin of 7.1% compared to Natera, Inc.'s net margin of -14.6%. Natera, Inc.'s return on equity of -15.66% beat GeneDx Holdings Corp.'s return on equity of -7.62%.

Natera, Inc. has a consensus price target of $259.11, signalling upside risk potential of 24.58%. On the other hand GeneDx Holdings Corp. has an analysts' consensus of $148.89 which suggests that it could grow by 124.91%. Given that GeneDx Holdings Corp. has higher upside potential than Natera, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Natera, Inc..

Natera, Inc. has a beta of 1.683, which suggesting that the stock is 68.297% more volatile than S&P 500. In comparison GeneDx Holdings Corp. has a beta of 2.173, suggesting its more volatile than the S&P 500 by 117.333%.

Natera, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeneDx Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera, Inc. pays -- of its earnings as a dividend. GeneDx Holdings Corp. pays out -- of its earnings as a dividend.

Natera, Inc. quarterly revenues are $665.5M, which are larger than GeneDx Holdings Corp. quarterly revenues of $121M. Natera, Inc.'s net income of $47.3M is higher than GeneDx Holdings Corp.'s net income of -$17.7M. Notably, Natera, Inc.'s price-to-earnings ratio is -- while GeneDx Holdings Corp.'s PE ratio is 1,444.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera, Inc. is 12.66x versus 4.53x for GeneDx Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.